US2023034467A1PendingUtilityA1

Engineered HCV E2 Immunogens and Related Vaccine Compositions

60
Assignee: SCRIPPS RESEARCH INSTPriority: Jul 26, 2019Filed: Dec 17, 2021Published: Feb 2, 2023
Est. expiryJul 26, 2039(~13 yrs left)· nominal 20-yr term from priority
Inventors:Linling HeJiang ZhuErick GiangMansun LawIan A. WilsonNetanel Tzarum
C12N 7/00A61K 2039/575C12N 2770/24234A61K 39/29A61K 47/6929A61K 39/12C07K 14/005A61P 31/14A61K 39/385A61K 47/6935C12N 2770/24222A61K 2039/55555
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides novel engineered HCV E2 polypeptide immunogens and related vaccine compositions that display the engineered E2 polypeptides. The invention also provides methods of using such immunogens and vaccine compositions in various therapeutic applications, e.g., for preventing or treating HCV infections.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A modified HCV E2 ectodomain polypeptide, comprising an engineered E2 ectodomain sequence.

Join the waitlist — get patent alerts

Track US2023034467A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.